Ultragenyx Pharmaceutical Inc
For the period ended Dec 31, 2023. Filed Feb 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 21, 2024
RARE$16.41+6.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(In thousands, except share and per share amounts)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Revenues: | |||
| Product sales | $180,413 | $118,927 | $77,017 |
| Royalty revenue | 182,652 | 21,692 | 17,951 |
| Collaboration and license | 71,184 | 222,710 | 256,438 |
| Total revenues | 434,249 | 363,329 | 351,406 |
| Operating expenses: | |||
| Cost of sales | 45,209 | 28,320 | 16,008 |
| Research and development | 648,449 | 705,789 | 497,153 |
| Selling, general and administrative | 309,799 | 278,139 | 219,982 |
| Total operating expenses | 1,003,457 | 1,012,248 | 733,143 |
| Loss from operations | (569,208) | (648,919) | (381,737) |
| Interest income | 26,688 | 11,074 | 1,928 |
| Change in fair value of equity investments | 397 | (19,299) | (42,063) |
| Non-cash interest expense on liabilities for sales of future royalties | (66,004) | (43,015) | (29,422) |
| Other expense | (337) | (1,566) | (1,687) |
| Loss before income taxes | (608,464) | (701,725) | (452,981) |
| Benefit from (provision for) income taxes | 1,825 | (5,696) | (1,044) |
| Net loss | $(606,639) | $(707,421) | $(454,025) |
| Net loss per share, basic and diluted | $(8.25) | $(10.12) | $(6.70) |
| Shares used in computing net loss per share, basic and diluted | 73,543,862 | 69,914,225 | 67,795,540 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.